Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

You may be eligible if

• Histologically confirmed mantle cell lymphoma OR indolent B-cell lymphoproliferative disorders of any of the following types:
• * Chronic lymphocytic leukemia
• * Small lymphocytic lymphoma
• * Follicular center cell non-Hodgkin's lymphoma (grade I or II)
• * Marginal zone lymphoma
• * Waldenstrom's macroglobulinemia
• * Hairy cell leukemia
• Previously untreated or relapsed/refractory disease
• No evidence of histological transformation to an intermediate-grade or aggressive lymphoma
• CD20 positive by immunoperoxidase or flow cytometry
• Evaluable disease with presence of 1 of the following criteria:
• * Absolute lymphocyte count greater than 5,000/mm\^3
• * At least 1 measurable node greater than 2 cm by computed tomography (CT) scan OR measurable disease in a lymphoid structure (spleen)
• * Bone marrow involvement (greater than 20% of marrow cellularity)
• Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
• See Disease Characteristics
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 9.0 g/dL
• Bilirubin no greater than 2 times normal
• Aspartate aminotransferase (AST) no greater than 2 times normal
• Creatinine no greater than 2.0 mg/dL
• Creatinine clearance at least 50 mL/min
• No renal dysfunction that would impair tolerance or compliance with study therapy
• No cardiac dysfunction that would impair tolerance or compliance with study therapy
• No pulmonary dysfunction that would impair tolerance or compliance with study therapy
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No chronic gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that would impair tolerability of compliance with therapy
• No neurological or psychiatric dysfunction that would impair tolerability of or compliance with study therapy
• At least 6 weeks since prior nitrosourea or mitomycin
• No more than 6 prior courses of fludarabine
• No concurrent corticosteroids as antiemetics
• At least 4 weeks since prior therapy for disease
• No more than 3 prior treatments for disease (not including steroids alone)